期刊文献+

0.1%他克莫司滴眼液治疗难治性免疫相关性角膜病效果观察

0.1% tacrolimus eye drops in the treatment of refractory immune associated keratopathy
下载PDF
导出
摘要 目的:探讨0.1%他克莫司滴眼液治疗难治性免疫相关性角膜病的效果。方法:收治难治性免疫相关性角膜病患者100例,随机分为观察组和对照组。对照组实施羊膜移植治疗,观察组在对照组基础上联合他克莫司滴眼液治疗。结果:观察组总有效率高于对照组(P<0.05)。治疗后观察组患者视力值优于对照组(P<0.05)。结论:0.1%他克莫司滴眼液治疗难治性免疫相关性角膜病患者,效果显著。 Objective:To investigate the effect of tacrolimus 0.1%eye drops in the treatment of refractory immune related keratopathy.Methods:100 patients with refractory keratokeratopathy were randomly divided into the observation group and the control group.The control group were treated with amniotic membrane transplantation,and the observation group were treated with tacrolimus eye drops on the basis of the treatment given in the control group.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After the treatment,the visual acuity of the observation group was better than that of the control group(P<0.05).Conclusion:0.1%tacrolimus eyedrops in the treatment of refractory immune related keratopathy has achieved significant results.
作者 刘海英 Liu Haiying(Department of Ophthalmology,the People's Hospital of Taiyuan City in Shanxi Province,Shanxi Taiyuan 030001)
出处 《中国社区医师》 2018年第23期26-26,28,共2页 Chinese Community Doctors
关键词 他克莫司滴眼液 难治性免疫相关性角膜病 效果 Tacrolimus eye drops Intractable immuno related keratopathy Effect
  • 相关文献

参考文献2

二级参考文献24

  • 1Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease[ J ]. Ophthalmology ,2005,112( 8 ) : 1472-1477.
  • 2Baker KB, Spurrier N J, Watkins AS, et al. Retention time h~r corticosleroid-sparing systemic immunosuppressive agents in patients with inflammalory eye disease[ J ]. Br J Ophthahnol, 2006,90 ( 12 ) : 1481 - 1485. doi: 10. 1156/bjo. 2006. 097998.
  • 3Galor A, Thorrle JE. Seleritis and peripheral ulcerative keratitis [ J ]. Rheum Dis Clin North Am,2007,33 (4) : 835-854. doi: 10. 1016/j. rdc. 2007.08. 002.
  • 4Messmer EM, Foster CS. Yasculitic peripheral ulcerative keratitis [ J ]. Surv Ophthalmol, 1999,43 ( 5 ) : 379-396.
  • 5Yagei A. Update on peripheral ulcerative keratitis [ J ]. Clin Ophthalmol,2012,6 : 747-754. doi : 10. 2147/OPTH. $24947.
  • 6Tung TH. Tacrolimus ( FK506 ) : Safety and Applications in Reconstructive Surgery[J]. Hand (N Y) ,2010,5 (1) : 1-8. doi: 10. 1007/s11552-009- 9193-8.
  • 7Hoekstra HJ,Hawkins K,de Boer WJ,et al. Gastrointestinal complications in lung transplant survivors that require surgical intervention [ J ]. Br J Surg,2001,88(3) :433-438. doi:10. 1046/j. 1365-2168. 2001. 01693. x.
  • 8Sloper CM ,Powell RJ, Dua HS. Tacrolimus ( FK506 ) in the treatment of posterior uveitis refractory to cyclosporine [ J ]. Ophthalmology, 1999, 106 (4) : 723 -728.
  • 9Lo YH, Cheng GS, Huang CC, et al. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo [ J ]. J Dermatol, 2010,37(2) : 125-129. doi:10, llll/j. 1346-8138.2009.00774. x.
  • 10Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis[J]. J Am Acad Dermatol,2004,51 (5) : 723-730.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部